TY - GEN
T1 - Erratum: Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study
AU - Hoerauf, Achim
AU - Specht, Sabine
AU - Büttner, Marcelle
AU - Pfarr, Kenneth
AU - Mand, Sabine
AU - Fimmers, Rolf
AU - Marfo-Debrekyei, Yeboah
AU - Konadu, Peter
AU - Debrah, Alexander Yaw
AU - Bandi, Claudio
AU - Brattig, Norbert
AU - Albers, Anna
AU - Larbi, John
AU - Batsa, Linda
AU - Taylor, Mark
AU - Adjei, Ohene
AU - Büttner, Dietrich W.
PY - 2008/9/1
Y1 - 2008/9/1
N2 - In a randomized, placebo-controlled trial in Ghana, 67 onchocerciasis patients received 200-mg/day doxycycline for 4-6 weeks, followed by ivermectin (IVM) after 6 months. After 6-27 months, efficacy was evaluated by onchocercoma histology, PCR and microfilariae determination. Administration of doxycycline resulted in endobacteria depletion and female worm sterilization. The 6-week treatment was macrofilaricidal, with >60% of the female worms found dead, despite the presence of new, Wolbachia-containing worms acquired after the administration of doxycycline. Doxycycline may be developed as second-line drug for onchocerciasis, to be administered in areas without transmission, in foci with IVM resistance and in areas with Loa co-infections.
AB - In a randomized, placebo-controlled trial in Ghana, 67 onchocerciasis patients received 200-mg/day doxycycline for 4-6 weeks, followed by ivermectin (IVM) after 6 months. After 6-27 months, efficacy was evaluated by onchocercoma histology, PCR and microfilariae determination. Administration of doxycycline resulted in endobacteria depletion and female worm sterilization. The 6-week treatment was macrofilaricidal, with >60% of the female worms found dead, despite the presence of new, Wolbachia-containing worms acquired after the administration of doxycycline. Doxycycline may be developed as second-line drug for onchocerciasis, to be administered in areas without transmission, in foci with IVM resistance and in areas with Loa co-infections.
U2 - 10.1007/s00430-007-0072-z
DO - 10.1007/s00430-007-0072-z
M3 - Other contribution
VL - 197
T3 - Medical Microbiology and Immunology
ER -